Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
November 6, 2018 4:15 PM ESTTotal revenue of $103.0 million, a 28% increase over 2017Net product sales of $100.2 million, a 28% increase over 2017Operating earnings of $37.5 million, a 68% increase over 2017Diluted earnings per share (GAAP) of $0.52, a 79% increase over 2017Data from first three Phase III SPN-812 trials expected in December 2018Acquisition of Biscayne Neurotherapeutics, Inc. closed in October 2018Ranked #1 fastest growing pharmaceutical company worldwide per Fortune 100 fastest growing companies
ROCKVILLE, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for... More
